Navigation Links
Prime Therapeutics Urges Caution on Mandates of Abuse-Deterrent Formulations of Opioids Citing Value Concerns
Date:7/20/2017

ST. PAUL, Minn., July 20, 2017 /PRNewswire/ -- Prime Therapeutics LLC (Prime) released this statement from its Chief Medical Officer, Jonathan Gavras, M.D., following today's Institute for Clinical and Economic Review's (ICER) public meeting reviewing its report on the effectiveness and value of abuse-deterrent formulations (ADF) of opioids. Prime was the sole pharmacy benefit manager on the policy roundtable at the meeting.

"The ICER data suggests there is not a material cost benefit to the use of abuse-deterrent formulations (ADF) in opioids in terms of overall cost vs. abuse-deterrent capability that they provide. We at Prime Therapeutics (Prime) believe opioids play an important role in pain management; however, we remain concerned about overprescribing of ADF opioids, especially when they can still be used in excess quantities and for illegitimate means. The fact is these products have not shown that they materially improve outcomes. If laws mandate ADFs over traditional opioids it will add billions of dollars to the U.S. health care system with limited benefits, and may even lead to unintended negative consequences of alternative narcotic abuse. While Prime supports ADF technology, these formulations alone are not going to solve the epidemic, and thus shouldn't consume a disproportionate amount of the dollars to address the epidemic, which will happen if their use is mandated. With so many lives at stake, policy makers and the healthcare industry need to stay focused on backing comprehensive, evidence-based solutions."

The voting body at the public meeting concluded:

  • there was not enough evidence to demonstrate a reduced risk of abuse for people using immediate-release ADF RoxyBondTM over a non-ADF immediate release opioid.  
  • there was enough evidence of reduced risk of abuse to support using the extended-release ADF OxyContin® over its non-ADF opioid counterparts, but there was not enough evidence to support using other extended release ADF opioids.  
  • there was not enough evidence to demonstrate a net health benefit on a population level with the use of Oxycontin® vs. non-ADF extended release opioids.  
  • that the most appropriate public policy to pursue is to develop a way for physicians to work for payers, policy makers and addiction treatment centers to target ADFs to the highest risk people to help guide the prescriber in their decision making.
  • For details on the questions and results visit @icer_review on Twitter.

    About Prime Therapeutics
    Prime Therapeutics LLC (Prime) helps people get the medicine they need to feel better and live well. Prime manages pharmacy benefits for health plans, employers, and government programs including Medicare and Medicaid. The company processes claims and delivers medicine to members, offering clinical services for people with complex medical conditions. Prime serves more than 20 million people. It is collectively owned by 14 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans.


    Contact:

    Karen Lyons, APRPrime TherapeuticsDirector, Corporate Communications612.777.5742KLyons@primetherapeutics.com

     

    View original content:http://www.prnewswire.com/news-releases/prime-therapeutics-urges-caution-on-mandates-of-abuse-deterrent-formulations-of-opioids-citing-value-concerns-300491983.html


    '/>"/>
    SOURCE Prime Therapeutics LLC
    Copyright©2017 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Research Reports Initiation on Biotech Stocks -- Epizyme, Sierra Oncology, Five Prime Therapeutics, and AveXis
    2. Paramed: Primer escáner MRI abierto en Gales y el séptimo sistema en el Reino Unido
    3. BioMarin Receives Access to Priority Medicines (PRIME) Regulatory Support from EMA for BMN 270 Gene Therapy in Hemophilia A
    4. Prime Therapeutics is Certified for NCQA Utilization Management and Health Information Products - Pharmacy Benefit Information
    5. Takara Bio USA, Inc. and TeselaGen Biotechnology, Inc. Release a Powerful New Primer Tool for Easy Design of In-Fusion Cloning Experiments
    6. 22 compañías biofarmacéuticas lanzan la primera iniciativa para abordar las enfermedades no comunicables
    7. Prime Therapeutics fills new chief of sales position
    8. Two Prime Therapeutics pharmacists achieve awards from Academy of Managed Care Pharmacy
    9. Prime Therapeutics Research Finds Increase in Insulin Use, Pharmacy Expense
    10. Prime Therapeutics Releases Studies on Efforts to Reduce Opioid Abuse, Misuse
    11. Prime Therapeutics Statement on U.S. Food and Drug Administrations Approval of Biosimilar Inflectra
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2019)... ... ... DidCBDWork.com is the first website aimed at crowdsourcing an important ... work? It seems like depending on what you read, CBD is either a miracle ... testimonials of real CBD users, who are attempting to ease real conditions, to rate ...
    (Date:7/10/2019)... ... 2019 , ... Successful actor and philanthropist, Laurence Fishburne, is ... of healthcare and how these costs affect American consumers. , The episode addresses ... painful decisions families face between paying for essential health services they require and ...
    (Date:7/9/2019)... ORION, Mich. (PRWEB) , ... July 10, 2019 ... ... The specialists at Women’s Excellence fully understand Menopause and provide in-depth interpretation ... to develop a personalized menopausal management plan. , “We value your wants and ...
    Breaking Medicine Technology:
    (Date:7/13/2019)... ... July 13, 2019 , ... ZALO , the ... and innovative rechargeable vibrator and clitoral massager. To view the product and its accompanying ... newest and most advanced, personal massagers to people around the world,” said Mara Epstein, ...
    (Date:7/13/2019)... , ... July 12, 2019 , ... ... and CUBIO Innovation Center , sponsored by Hangzhou Investment Promotion Bureau, ... on June 2, 2019. , The conference attracted Fosun Pharmaceuticals, WuXi Biologics, Kelun ...
    (Date:7/11/2019)... ... 2019 , ... Swagelok Southeast Texas, a distributor for Ohio-based ... acquisition of another Houston-area distributor. The acquisition of the Swagelok Central Houston facility ... Nederland and Houston. , With this expansion, Swagelok Southeast Texas also extends ...
    (Date:7/10/2019)... ... July 10, 2019 , ... ... just announced that Olympians Lolo Jones and Kerri Walsh Jennings have officially joined ... provide CBD education and brand awareness to athletes, fans, and consumers around the ...
    (Date:7/9/2019)... ... ... Women’s Excellence is pleased to offer a comprehensive women’s health blog on their ... women’s health information, current events, advancements in healthcare technology, and news and updates about ... to offer a new women’s health blog written by our team on topics that ...
    Breaking Medicine News(10 mins):